#1 Clinical Trials Search in Europe

Gadoteric Acid

Gadoteric acid, also known as Dotarem, is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) to enhance image quality and improve diagnostic accuracy. This article explores various clinical trials investigating the use of gadoteric acid in different medical conditions and patient populations, including its safety profile and effectiveness in enhancing MRI scans.

Table of Contents

What is Gadoteric Acid?

Gadoteric acid, also known by its brand names Dotarem or Gd-DOTA, is a type of medication used in medical imaging[1]. It belongs to a class of drugs called gadolinium-based contrast agents (GBCAs). These agents are used to enhance the quality of magnetic resonance imaging (MRI) scans, making certain structures in the body more visible to doctors[2].

Uses of Gadoteric Acid

Gadoteric acid is primarily used in the following situations:

  • Non-coronary MR angiography: This is a type of imaging used to examine blood vessels outside of the heart. It can help diagnose conditions like arterial occlusive disease, which is a narrowing or blockage of arteries[2].
  • Brain and inner ear imaging: Gadoteric acid can help visualize structures in the brain and inner ear, which is useful in diagnosing conditions like Meniere’s disease, a disorder of the inner ear that can cause vertigo and hearing loss[3].
  • General MRI enhancement: It’s used to improve the visibility of various structures throughout the body during MRI scans[1].

How Gadoteric Acid Works

Gadoteric acid works by altering the magnetic properties of water molecules in the body. When a patient undergoes an MRI after receiving gadoteric acid, the contrast agent causes certain areas to appear brighter or darker on the resulting images. This enhanced contrast helps doctors better visualize and distinguish between different types of tissues and structures in the body[3].

Safety and Side Effects

While gadoteric acid is generally considered safe, like all medications, it can cause side effects in some patients. Common side effects may include:

  • Headache
  • Nausea
  • Dizziness
  • Injection site reactions (such as pain or coldness)
  • Feeling of warmth

In rare cases, more serious allergic reactions can occur. These may include symptoms like hives, difficulty breathing, or swelling of the face, lips, tongue, or throat[1].

Special Considerations

Patients with kidney problems require special consideration when using gadoteric acid. This is because the kidneys are responsible for eliminating the contrast agent from the body. In people with severely impaired kidney function, there is a rare but serious risk of developing a condition called nephrogenic systemic fibrosis (NSF), which causes thickening and hardening of the skin and internal organs[4].

It’s important to note that gadoteric acid is considered a macrocyclic GBCA, which is thought to be more stable and potentially safer than linear GBCAs, especially in patients with kidney problems[4].

Ongoing Research

Researchers continue to study gadoteric acid to better understand its safety profile and potential uses. Some areas of ongoing research include:

  • Use in children under 2 years of age: Studies are being conducted to assess the safety and effectiveness of gadoteric acid in very young children[1].
  • Comparison with other contrast agents: Researchers are comparing gadoteric acid with other types of contrast agents to determine their relative safety and effectiveness, particularly in patients with kidney problems[4].
  • Use in specific conditions: Studies are exploring the use of gadoteric acid in imaging specific conditions, such as osteoarthritis of the knee[5].

As with any medical procedure or medication, it’s important to discuss the use of gadoteric acid with your healthcare provider. They can provide personalized advice based on your specific health situation and the reason for your MRI scan.

Aspect Details
Primary Uses MRI contrast agent for enhancing image quality in various body structures
Patient Populations Studied Adults, children under 2 years, patients with mild to moderate renal insufficiency
Conditions Investigated Inner ear and brain imaging, non-coronary MR angiography, heart failure with preserved ejection fraction
Safety Assessments Monitoring of adverse events, changes in vital signs, ECG, and biomarkers
Comparative Studies Comparison with other contrast agents (e.g., gadodiamide) for safety and efficacy
Long-term Follow-up Some studies include follow-up periods of up to 24 months
Special Considerations Caution in patients with severe renal dysfunction (GFR <30)

FAQ

  • What is gadoteric acid used for in clinical trials? Gadoteric acid is primarily used as a contrast agent in MRI scans to enhance image quality and improve the visibility of various structures in the body. Clinical trials are investigating its use in different conditions, such as inner ear and brain imaging, non-coronary MR angiography, and in patients with mild to moderate renal insufficiency.
  • Is gadoteric acid safe for children under 2 years of age? A clinical trial (NCT02609919) is specifically assessing the safety of Dotarem (gadoteric acid) in children under 2 years of age. The study aims to monitor for any adverse events up to 24 hours after injection and evaluate image quality improvement with contrast.
  • How does gadoteric acid compare to other contrast agents? One study (NCT04776187) is comparing the safety of gadoteric acid (a macrocyclic agent) to gadodiamide (a linear agent) in patients with mild to moderate renal insufficiency. The trial is evaluating the incidence of adverse events and changes in various biomarkers.
  • What are the potential side effects of gadoteric acid? While generally considered safe, potential side effects being monitored in clinical trials include headache, nausea, injection site reactions, allergic reactions, and changes in vital signs. The studies are also assessing long-term safety through follow-up periods of up to 24 months.
  • Can gadoteric acid be used in patients with kidney problems? Clinical trials are investigating the use of gadoteric acid in patients with mild to moderate renal insufficiency. However, patients with severe kidney problems (GFR <30) are typically excluded from these studies due to potential risks associated with gadolinium-based contrast agents in this population.

Ongoing Clinical Trials on Gadoteric Acid

  • Efficacy and safety of gadopiclenol versus gadoteric acid‑enhanced MRA in adult patients with suspected vascular disease

    Recruiting

    3 1 1 1
    Investigated drugs:
    Czechia France Germany Hungary Italy Poland +1

  • Study on the Effects of Different Doses of Adenosine for Patients with Chronic Coronary Syndrome, with and without Heart Failure

    Recruiting

    3 1 1 1
    Investigated drugs:
    Sweden

  • Study on Low-Dose Gadolinium for Breast Cancer MRI in Patients Using Gadoteric Acid

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Use of 18F-PSMA-1007, Hyoscine Butylbromide, and Gadoteric Acid in Imaging for Patients with High-Risk Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on Improving Ovarian Cancer Diagnosis Using Pyruvic Acid and Gadoteric Acid for Patients Suspected of Having Ovarian Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of ropivacaine, sodium chloride and gadoteric acid in nerve blocks for hip pain in healthy volunteers

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Theophylline, Gadoteric Acid, and Regadenoson for Patients with Chronic Total Coronary Artery Blockage

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Long-Term Effects of Gadoxetic Acid, Gadoteridol, and Gadobenate Dimeglumine on Motor and Cognitive Functions in Healthy Adults

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy

  • Study on Manganese Uptake in Heart Failure Patients Using Mangafodipir Trisodium and Gadoteric Acid

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Norway

  • Study on [18F]-Fludarabine and Gadoteric Acid for Imaging in Patients with Newly Diagnosed Primary CNS Lymphoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Gadoteric acid: A gadolinium-based contrast agent used in magnetic resonance imaging (MRI) to enhance image quality and improve diagnostic accuracy.
  • MRI: Magnetic Resonance Imaging, a non-invasive imaging technique that uses strong magnetic fields and radio waves to create detailed images of the body's internal structures.
  • Contrast agent: A substance used to improve the visibility of internal body structures in imaging techniques such as MRI.
  • Gadolinium: A rare earth element used in contrast agents for MRI due to its magnetic properties.
  • Dotarem: A brand name for gadoteric acid, used as a contrast agent in MRI scans.
  • Angiography: An imaging technique used to visualize blood vessels and organs in the body.
  • Renal insufficiency: A condition where the kidneys are not functioning properly, which can affect the body's ability to filter and excrete substances, including contrast agents.
  • GFR: Glomerular Filtration Rate, a measure of kidney function used to assess the severity of renal insufficiency.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Macrocyclic agent: A type of gadolinium-based contrast agent with a ring-like molecular structure, generally considered more stable than linear agents.
  • Linear agent: A type of gadolinium-based contrast agent with a linear molecular structure, which may be less stable than macrocyclic agents.
  • Nephrogenic Fibrosing Dermopathy: A rare condition characterized by thickening and hardening of the skin, potentially associated with the use of gadolinium-based contrast agents in patients with severe kidney dysfunction.

References

  1. https://clinicaltrials.gov/study/NCT02609919
  2. https://clinicaltrials.gov/study/NCT00447889
  3. https://clinicaltrials.gov/study/NCT02529475
  4. https://clinicaltrials.gov/study/NCT04776187
  5. https://clinicaltrials.gov/study/NCT06704932